19:31 , Jan 24, 2018 |  BC Innovations  |  Emerging Company Profile

D over L for diabetes

ImmunoMolecular Therapeutics LLC’s small molecule inhibitor of an HLA-DQ8 peptide could treat Type I diabetes without courting the broad-spectrum immunosuppression of other disease-modifying therapies in development. About 60% of Type I diabetes patients carry the...
21:28 , Nov 10, 2017 |  BC Week In Review  |  Company News

IM Therapeutics launches with T1D candidate

Autoimmune company ImmunoMolecular Therapeutics LLC (Broomfield, Colo.) emerged from stealth mode with a small molecule candidate that aims to treat Type I diabetes by preventing the initiation of the autoimmune response against insulin-producing beta cells....
05:01 , Nov 9, 2017 |  BC Extra  |  Company News

IM Therapeutics emerges from stealth with small molecule for T1D

ImmunoMolecular Therapeutics LLC (Broomfield, Colo.) emerged from stealth mode with a small molecule candidate that aims to treat Type I diabetes by preventing the initiation of the autoimmune response against insulin-producing beta cells. The company...
08:00 , Feb 19, 2015 |  BC Innovations  |  Product R&D

Banking on stem cells

While stem cell developers wrestle with fine-tuning cell types, improving protocols and calling for better regulatory guidelines, few in the field are addressing one of the looming problems likely to hit once more products reach...
07:00 , Mar 26, 2012 |  BioCentury  |  Emerging Company Profile

ImmusanT: Having their cake

ImmusanT Inc. is developing what could be the first treatment for celiac disease that allows patients to eat a normal diet. The company's Nexvax2 vaccine seeks to reprogram CD4+ T cells to induce gluten tolerance....
08:00 , Dec 19, 2011 |  BioCentury  |  Finance

Bread for celiac vaccine

Bread for celiac vaccine ImmusanT Inc. is working on a peptide-based therapeutic vaccine designed to address the underlying problem in celiac disease, and received $20 million in series A money last week to pursue proof-of-concept...
02:44 , Dec 14, 2011 |  BC Extra  |  Financial News

ImmusanT raises $20M in series A

ImmusanT Inc. (Cambridge, Mass.) raised $20 million in a series A round from Vatera Healthcare Partners. ImmusanT is developing Nexvax2 , an immunotherapy vaccine comprised of gluten peptides to treat celiac disease in patients with...
07:00 , Mar 27, 2008 |  BC Innovations  |  Targets & Mechanisms

Celiac Attack

The only current treatment for celiac disease, a disorder of the small intestine that results from a hypersensitivity to ingested gluten, is lifelong adherence to a gluten-free diet. However, it is difficult to follow such...